Pfizer's $43 million stake in Nimbus boosts NASH therapy research and development

Pharmaceuticals, March 20 (Upi) -- Nimbus Therapeutics, a well-known preclinical research firm, said it had completed a total of $43 million in B-round financingThe financing of pharmaceutical giant Pfizer's name is on the list, suggesting that another biopharmaceutical giant will be behind The Development of Nimbusin addition to Pfizer Ventures, GlaxoSmithKline's SR One, Lilly Ventures and other prominent investment firms active in bio
pharmaceutical, even billionaire Bill Gates has joined inNimbus Therapeutics, which had previously used the company's unique technology to conduct computer-simulated drug screening services for major biopharmaceutical companies, and under the leadership of new CEO Don Nicholson, the company will gradually enter the field of clinical research, and the company has specifically replaced "Discovery" in the company's name with "Spa" to announce the shift in the company's future focusthe financing, Nimbus will begin clinical research on its first drugThe drug is an acetyl coenzyme a calyse inhibitor(CAA) and is primarily used to treat non-alcoholic fatty hepatitis (NASH)Don Nicholson claims that this is also the first CAA inhibitor drug to date for NASHWith the improvement of people's living standards, there are hundreds of millions of patients with fatty liver disease in the world, it can be said that NASH has become a threat to humanhealthone of the importantdiseasesAs a result, NASH is considered the next gold mine for biopharmaceutical developersNimbus plans to use this investment to advance the drug into clinical research, which is expected to begin in the first half of 2016In addition, the company also disclosed that the company has signed two separate cooperation projects with Shire and Monsanto, but did not disclose specific details